FeesSafety
Pluang+

Claims of 130M Dogecoin bought by large holders lack verifiable details, raising doubts.

Market News
08 Nov 2026, 18:51 WIB
Tokenpost
View Source
Neutral
Claims of 130M Dogecoin bought by large holders lack verifiable details, raising doubts.

A claim by DogeGod that large holders purchased 130 million Dogecoin over two days lacks essential details such as dates, wallet addresses, transaction IDs, or calculation methods. Without this information, the figure cannot be verified against on-chain activity. An earlier claim of 600 million Dogecoin bought in 48 hours also lacked transparency, casting further doubt on these numbers. This absence of verifiable data makes it difficult for investors to assess the true scale of Dogecoin accumulation by large holders.

DogeGod's claim of large holders acquiring 130 million DOGE in two days is presented here with Pluang's cryptocurrency market data for context. For readers following major cryptocurrencies, as of Nov 08, 2026 23:21 WIB, 13 out of 50 priced assets rose while 36 fell. Among notable movers, GRT (The Graph) dropped 3.63% to Rp335 with a typical hold time of 100 days and 99% buy orders, contrasting with XNO (Nano) which rose 3.17% to Rp5,851 despite 100% sell orders, and XTZ (Tezos) fell 3.56% to Rp4,605 with a near-even order split.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
1 hour ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
1 hour ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
2 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
2 hours ago
PEPE token breaks above descending trendline, hinting at potential trend reversal but needs confirmation.

PEPE token breaks above descending trendline, hinting at potential trend reversal but needs confirmation.

The PEPE token has moved above a descending trendline after a prolonged decline, breaking out of a broader downward channel. This breakout changes the chart structure, signaling a potential trend reversal. However, this move requires further confirma...

Technical Signals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App